The Cancer Genome Atlas (TCGA) pan-cancer datasets have profiled a comprehensive catalog of PI3K/Akt/mTOR-associated variants across 10,000 tumors and represent a valuable resource for both understanding the PI3K/Akt/mTOR pathway deregulation in cancers and translating this information in clinical utility for personalized treatments [27,28,29]. This evidence concerns the gene AKT1 and cancer.